• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Redhill Biopharma Ltd.

    12/23/25 4:05:16 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $RDHL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    RedHill Biopharma Ltd.

    (Name of Issuer)


    American Depositary Shares

    (Title of Class of Securities)


    757468301

    (CUSIP Number)


    12/19/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    757468301


    1Names of Reporting Persons

    YA II PN, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    508,723.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    508,723.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    508,723.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Pursuant to the Standby Equity Distribution Agreement (the "SEPA") entered into on December 19, 2025 between YA II PN, Ltd. ("YA II") and RedHill Biopharma Ltd. (the "Issuer"), YA II received 508,723 American Depositary Shares (the "ADSs") representing ordinary shares (the "Shares") of the Issuer, and received a warrant (the "Warrant") to purchase an additional 590,446 ADSs. YA II is prohibited from acquiring any ADSs pursuant to the SEPA or the Warrant which when aggregated with all other ADSs then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the ADSs outstanding. Calculation based on 5,092,326 ADSs, consisting of 4,583,603 ADSs outstanding as of December 19, 2025, plus an additional 508,723 ADSs received by YA II pursuant to the SEPA.


    SCHEDULE 13G

    CUSIP No.
    757468301


    1Names of Reporting Persons

    YA Global Investments II (U.S.), LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    508,723.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    508,723.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    508,723.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Pursuant to the SEPA, YA II received 508,723 ADSs representing Shares of the Issuer and received the Warrant to purchase an additional 590,446 ADSs. YA II is prohibited from acquiring any ADSs pursuant to the SEPA or the Warrant which when aggregated with all other ADSs then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the ADSs outstanding. Calculation based on 5,092,326 ADSs, consisting of 4,583,603 ADSs outstanding as of December 19, 2025, plus an additional 508,723 ADSs received by YA II pursuant to the SEPA.


    SCHEDULE 13G

    CUSIP No.
    757468301


    1Names of Reporting Persons

    Yorkville Advisors Global, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    508,723.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    508,723.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    508,723.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Pursuant to the SEPA, YA II received 508,723 ADSs representing Shares of the Issuer and received the Warrant to purchase an additional 590,446 ADSs. YA II is prohibited from acquiring any ADSs pursuant to the SEPA or the Warrant which when aggregated with all other ADSs then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the ADSs outstanding. Calculation based on 5,092,326 ADSs, consisting of 4,583,603 ADSs outstanding as of December 19, 2025, plus an additional 508,723 ADSs received by YA II pursuant to the SEPA.


    SCHEDULE 13G

    CUSIP No.
    757468301


    1Names of Reporting Persons

    Yorkville Advisors Global II, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    508,723.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    508,723.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    508,723.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Pursuant to the SEPA, YA II received 508,723 ADSs representing Shares of the Issuer and received the Warrant to purchase an additional 590,446 ADSs. YA II is prohibited from acquiring any ADSs pursuant to the SEPA or the Warrant which when aggregated with all other ADSs then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the ADSs outstanding. Calculation based on 5,092,326 ADSs, consisting of 4,583,603 ADSs outstanding as of December 19, 2025, plus an additional 508,723 ADSs received by YA II pursuant to the SEPA.


    SCHEDULE 13G

    CUSIP No.
    757468301


    1Names of Reporting Persons

    YAII GP, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    508,723.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    508,723.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    508,723.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Pursuant to the SEPA, YA II received 508,723 ADSs representing Shares of the Issuer and received the Warrant to purchase an additional 590,446 ADSs. YA II is prohibited from acquiring any ADSs pursuant to the SEPA or the Warrant which when aggregated with all other ADSs then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the ADSs outstanding. Calculation based on 5,092,326 ADSs, consisting of 4,583,603 ADSs outstanding as of December 19, 2025, plus an additional 508,723 ADSs received by YA II pursuant to the SEPA.


    SCHEDULE 13G

    CUSIP No.
    757468301


    1Names of Reporting Persons

    YAII GP II, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    508,723.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    508,723.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    508,723.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Pursuant to the SEPA, YA II received 508,723 ADSs representing Shares of the Issuer and received the Warrant to purchase an additional 590,446 ADSs. YA II is prohibited from acquiring any ADSs pursuant to the SEPA or the Warrant which when aggregated with all other ADSs then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the ADSs outstanding. Calculation based on 5,092,326 ADSs, consisting of 4,583,603 ADSs outstanding as of December 19, 2025, plus an additional 508,723 ADSs received by YA II pursuant to the SEPA.


    SCHEDULE 13G

    CUSIP No.
    757468301


    1Names of Reporting Persons

    Mark Angelo
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    508,723.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    508,723.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    508,723.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Pursuant to the SEPA, YA II received 508,723 ADSs representing Shares of the Issuer and received the Warrant to purchase an additional 590,446 ADSs. YA II is prohibited from acquiring any ADSs pursuant to the SEPA or the Warrant which when aggregated with all other ADSs then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the ADSs outstanding. Calculation based on 5,092,326 ADSs, consisting of 4,583,603 ADSs outstanding as of December 19, 2025, plus an additional 508,723 ADSs received by YA II pursuant to the SEPA.


    SCHEDULE 13G

    CUSIP No.
    757468301


    1Names of Reporting Persons

    SC-Sigma Global Partners, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    508,723.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    508,723.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    508,723.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  Pursuant to the SEPA, YA II received 508,723 ADSs representing Shares of the Issuer and received the Warrant to purchase an additional 590,446 ADSs. YA II is prohibited from acquiring any ADSs pursuant to the SEPA or the Warrant which when aggregated with all other ADSs then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the ADSs outstanding. Calculation based on 5,092,326 ADSs, consisting of 4,583,603 ADSs outstanding as of December 19, 2025, plus an additional 508,723 ADSs received by YA II pursuant to the SEPA.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    RedHill Biopharma Ltd.
    (b)Address of issuer's principal executive offices:

    21 Ha'arba'a Street Tel Aviv, L3, 647392
    Item 2. 
    (a)Name of person filing:

    YA II PN, Ltd.
    (b)Address or principal business office or, if none, residence:

    1012 Springfield Ave., Mountainside, NJ 07092
    (c)Citizenship:

    Cayman Islands
    (d)Title of class of securities:

    American Depositary Shares
    (e)CUSIP No.:

    757468301
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    508,723
    (b)Percent of class:

    9.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    508,723

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    508,723

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    YA II is beneficially owned by YA Global Investments II (U.S.), LP (the "YA Feeder"). Yorkville Advisors Global, LP (the "YA Advisor") is the investment manager to YA II. Yorkville Advisors Global II, LLC (the "YA Advisor GP") is the general partner to the YA Advisor. YAII GP, LP (the "YA GP") is the general partner to the YA Feeder. YAII GP II, LLC (the "Yorkville GP") is the general partner to the YA GP. Mark Angelo makes the investment decisions on behalf of YA II. Accordingly, each of YA II, YA Feeder, the YA Advisor, the YA Advisor GP, the YA GP, the Yorkville GP and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of ADSs. YAII GP, LP is the general partner of SC-Sigma Global Partners, LP ("SC-Sigma"), which is an investor in YA II. YAII GP II, LLC is the general partner of YAII GP, LP. The YA Advisor is the investment manager to SC-Sigma. Accordingly, SC-Sigma, the YA GP, the Yorkville GP, the YA Advisor, and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of ADSs. For purposes of this filing, each of the reporting persons is deemed an affiliate of each other reporting person.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    YA II PN, Ltd.
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/23/2025
     
    YA Global Investments II (U.S.), LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/23/2025
     
    Yorkville Advisors Global, LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/23/2025
     
    Yorkville Advisors Global II, LLC
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/23/2025
     
    YAII GP, LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/23/2025
     
    YAII GP II, LLC
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/23/2025
     
    Mark Angelo
     
    Signature:/s/ Mark Angelo
    Name/Title:Mark Angelo
    Date:12/23/2025
     
    SC-Sigma Global Partners, LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:12/23/2025
    Get the next $RDHL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RDHL

    DatePrice TargetRatingAnalyst
    9/15/2021$23.00 → $21.00Buy
    HC Wainwright & Co.
    8/31/2021$22.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $RDHL
    SEC Filings

    View All

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    1/5/26 7:02:00 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form F-1 filed by Redhill Biopharma Ltd.

    F-1 - RedHill Biopharma Ltd. (0001553846) (Filer)

    12/31/25 5:09:48 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Redhill Biopharma Ltd.

    6-K - RedHill Biopharma Ltd. (0001553846) (Filer)

    12/31/25 4:58:07 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RDHL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

    RHB-1021 is a proprietary, advanced clinical-stage, once-daily, bimodal extended-release, oral tablet formulation of 5-HT3 antagonist, ondansetron, targeting oncology support, acute gastroenteritis and gastritis, IBS-D and GLP-1/GIP-associated gastrointestinal (GI) side effects -- Largey de-risked, RHB-102 development is supported by published positive U.S. Phase 3 & 2 results in gastroenteritis/gastritis and diarrhea-predominant irritable bowel syndrome (IBS-D) respectively, a positive comparative PK clinical study as part of the oncology support (CINV/RINV) program2, plus decades of ondansetron clinical use (>22 million annual U.S. ER prescriptions3) -- RHB-102 is clinically aligned, if ap

    1/5/26 7:00:00 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

    Resistance to venetoclax (Venclexta® and Venclyxto®, Abbvie / Genentech), the $2.5 billion blockbuster Chronic Lymphocytic Leukemia (CLL) therapy, is emerging as a therapeutic challenge, with leukemic cells persisting over time, even with combination therapy1 Studies show that sphingosine kinase 2 (SPHK2) is overexpressed in venetoclax-resistant cancer cells and that SPHK2 inhibition may reduce T-cell-induced activation and proliferation of venetoclax-resistant CLL cancer cells and resensitize previously resistant CLL cells2,3 New in vivo study shows adding opaganib, a potent SPHK2 inhibitor, to venetoclax reduces CLL cell (CD19⁺, CD5⁺) counts by 50% compared to controls and lowered CD3+, CD

    12/15/25 7:00:00 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

    TEL-AVIV, Israel and RALEIGH, N.C., Dec. 1, 2025 /PRNewswire/ -- RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that on November 26, 2025, it received confirmation from the Nasdaq Stock Market LLC ("Nasdaq") that the Company has regained compliance with the stockholders' equity requirement set forth in Nasdaq Listing Rule 5550(b)(1)1. This achievement aligns with RedHill's ongoing strategic initiatives in 2025, including the Talicia® partnership with Cumberland Pharmaceuticals and continued focus on operational efficiency. The Company was advised in this process by Donohoe Advisory. About RedHill Biopharma     RedHil

    12/1/25 7:00:00 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RDHL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    HC Wainwright & Co. reiterated coverage on Redhill Biopharma with a new price target

    HC Wainwright & Co. reiterated coverage of Redhill Biopharma with a rating of Buy and set a new price target of $21.00 from $23.00 previously

    9/15/21 6:06:43 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Redhill Biopharma with a new price target

    Cantor Fitzgerald initiated coverage of Redhill Biopharma with a rating of Overweight and set a new price target of $22.00

    8/31/21 6:48:45 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Redhill Biopharma downgraded by WBB Securities with a new price target

    WBB Securities downgraded Redhill Biopharma from Strong Buy to Buy and set a new price target of $16.00 from $17.00 previously

    5/28/21 7:52:50 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RDHL
    Leadership Updates

    Live Leadership Updates

    View All

    Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

    -       Dr. Almenoff brings more than 25 years of drug development and leadership experience to the Actinium Board of Directors   -       Dr. Almenoff to join Actinium's Nominating and Corporate Governance Committee NEW YORK, Nov. 4, 2024 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE:ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced the appointment of June Almenoff, M.D., Ph.D. to its Board of Directors. Dr. Almenoff is an accomplished biopharma executive with over 25 years of senior leadership and drug development experience. She currently serves as a Board Director and advisor to nu

    11/4/24 7:30:00 AM ET
    $ATNM
    $AVTX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RDHL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Redhill Biopharma Ltd.

    SC 13G/A - RedHill Biopharma Ltd. (0001553846) (Subject)

    11/14/24 12:22:08 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Redhill Biopharma Ltd.

    SC 13G - RedHill Biopharma Ltd. (0001553846) (Subject)

    2/2/24 4:10:29 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Redhill Biopharma Ltd.

    SC 13G - RedHill Biopharma Ltd. (0001553846) (Subject)

    2/1/24 10:22:43 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $RDHL
    Financials

    Live finance-specific insights

    View All

    CUMBERLAND PHAMACEUTICALS ANNOUNCES THE ADDITION OF AN ESTABLISHED FDA APPROVED PRODUCT TO ITS COMMERCIAL PORTFOLIO

     Cumberland to expand its gastroenterology offerings with the market-leading Helicobacter pylori therapy NASHVILLE, Tenn., Oct. 20, 2025 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX), a specialty pharmaceutical company focused on delivering high-quality products to improve patient care, announced strategic arrangements with RedHill Biopharma Ltd. (NASDAQ:RDHL), a specialty biopharmaceutical company, to jointly commercialize Talicia®. The FDA-approved oral capsule is indicated for the treatment of Helicobacter pylori infection in adults, a bacterial infection and leading risk factor for gastric cancer.

    10/20/25 9:05:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedHill's Talicia® Secures $4 Million Strategic Investment and U.S. Co-Commercialization Partnership Deal

    Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) invests $4 million in exchange for a 30% ownership stake and joint control in RedHill's Talicia business U.S. co-commercialization partnership designed to accelerate Talicia sales growth, leveraging Cumberland's expanded national sales promotion and marketing support, and deliver significant efficiencies through shared operational responsibility Transaction reinforces RedHill's financial position to advance its broader strategic objectives Patent protected through 2042 and with eight years QIDP market exclusivity, Talicia is:The #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1 Listed first-line H. pylori therapy in American Colle

    10/20/25 9:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    RedHill Biopharma Announces Q1/22 Highlights: On Track for Positive Cash from Operations in H2/22

    Targeting positive cash from operations to start during H2/22[1] Focus on earlier achievement of operational profitability thanks to a recently implemented comprehensive cost reduction plan, with expected operational cost savings of approximately $50 million over the next 18 months Continuous implementation of disciplined cost controls reduced Q1/22 cash used in operating activities by more than 70% to approximately $4 million, compared to approximately $15 million in Q4/21 Net revenues of $18.2 million in Q1/22; Cash balance[2] of $45 million as of March 31, 2022 Talicia® TRx up 12.8% over Q4/21 and Movantik® continues strong Q4/21 prescription performance Amendment improves key covenants i

    6/23/22 7:00:00 AM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care